[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100352446":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":34,"collaborators":20,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":20,"enrollmentInfo":45,"targetDuration":20,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":20,"overallStatus":54,"whyStopped":20,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Fosfomycin","EXPERIMENTAL","Fosomycin tromethamine, one sachet for 21 days",[13],"Drug: Fosfomycin Oral Suspension",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Fosfomycin Oral Suspension","Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days",[9],null,[22],{"facility":23,"status":20,"city":24,"state":20,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":20},"BOUILLER","Besançon","25000","France","FR",{"type":29,"coordinates":30},"Point",[31,32],6.01815,47.24878,{"lat":32,"lon":31},{"type":35,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100352446","phase-2-clinical-efficacy-of-fosfomycin-trometamol-per-os-in-the-treatment-of-documented-male-urinary-tract-infections-with-esbl-producing-enterobacteriaceae-with-esbl-producing-enterobacteriaceae-and-resistance-associated-with-fluoroquinolones-and-cotrimoxazole-fosfhom-100352446",false,"NCT03868969","Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)","FOSF'HOM","Inclusion Criteria:\n\n* clinical suspicion of urinary tract infection (UTI) defined by the presence of at least one of these signs: fever \\> 38°C and\u002For sus-pubic pain and\u002For dysuria and\u002For pollakiuria and\u002For urinary burns and\u002For macroscopic hematuria and\u002For acute urinary retention and\u002For pain with the rectal examination and\u002For confusion\n* And urinary analysis with leukocyturia \\> 10 \u002F mm3, bacteriuria \\> 10\\^3 CFU\u002FmL with ESBL producing enterobacteriaceae and resistance associated with fluoroquinolones (FQ) and cotrimoxazole (CTX) but sensitive to fosfomycin.\n\nExclusion Criteria:\n\n* allergy to fosfomycin and\u002For trometamol\n* Presence of material in the urinary tract\n* Severe immunosuppression\n* Chronic prostatitis\n* Prostate abscess\n* Acute pyelonephritis\n* Hemodynamic instability\n* Chronic renal failure (clearance \\\u003C60 mL\u002Fmin)\n* Prior antibiotic therapy, with an antibiotic sensitive on the antibiotic susceptibility test except: amoxicillin - clavulanic acid, cefixime, nitrofurantoin.\n* Co-treatment with metoclopramide","MALE","18 Years",{"count":46,"type":47},25,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2","The aim of the study was to evaluate the clinical and microbiological efficacy of fosfomycin trometamol (FT) per os in the treatment of documented male urinary tract infections with ESBL-producing enterobacteriaceae",[53],"Urinary Tract Infections","UNKNOWN","2019-03-08",{"date":57,"type":58},"2019-03-11","ACTUAL",{"date":60,"type":47},"2019-04",{"date":62,"type":47},"2021-09",{"name":5,"class":6},1]